GILD Stock DD Gilead Sciences, Inc. 11/04/2014 08:03:06

Message Board

Previous

| Next

Post# of 250691

Posted On: 11/04/2014 9:03:01 AM

Posted By: Rosner

GILD Gilead Sciences, Inc. $GILD Company Overview

Stock Message Board Recent Posts http://investorshangout.com/search?q=GILD&...mp;yt0=Go!

Last Updated: 11/04/2014 08:03:02

Current Price and Quotes
Last Price 109.98
Previous Close 112.00 Open 112.31
Daily Range 108.81 - 112.80 52wk Range 63.50 - 116.83
Volume 15,356,666 Dividend N/A
Average Vol (30d) 14,847,713 Yield N/A

Financials
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue 11,201,688 9,702,517 8,385,385 7,949,420
Cost of Revenue 2,858,502 2,471,363 2,124,410 1,869,876
Gross Profit 8,343,186 7,231,154 6,260,975 6,079,544
Operating Expenses

Research and Development 2,119,756 1,759,945 1,229,151 1,072,930
Sales, General and Admin. 1,699,431 1,461,034 1,241,983 1,044,392
Non-Recurring Items - - - -
Other - - - -
Operating Income 4,523,999 4,010,175 3,789,841 3,962,222
Income From Continuing Operations

Add'l Income/Expense Items (8,886) (37,279) 66,581 60,287
Earnings Before Interest and Tax 4,515,113 3,972,896 3,856,422 4,022,509
Interest Expense 306,894 360,916 205,418 108,961
Earnings Before Tax 4,208,219 3,611,980 3,651,004 3,913,548
Income Tax 1,150,933 1,038,381 861,945 1,023,799
Minority Interest (17,522) (17,967) (14,578) (11,508)
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations 3,074,808 2,591,566 2,803,637 2,901,257
Non Recurring Events

Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income 3,074,808 2,591,566 2,803,637 2,901,257
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders 3,074,808 2,591,566 2,803,637 2,901,257

Recent News
Source
Nov 4, 2014 Earnings Forecast Buzz for Alibaba, GT Advanced Technologies, GoPro, Plug Power, Gilead Sciences, and American Realty Capital Properties PR NEWSWIRE
Nov 4, 2014 Life-Science New Build Report: 200 New North American Sites in Planning Represent Potential $15 Billion Investment, an Industrial Info News Alert Marketwired
Nov 4, 2014 Gilead Sciences Once Again Tops the List of California's Most Honored Companies in Institutional Investor's All-America Executive Team Ranking Marketwired
Nov 4, 2014 Is AbbVie's Bullishness On Its Hepatitis C Drugs Valid? Seeking Alpha
Nov 3, 2014 Research and Markets: Gilead Sciences Clinical Development Profile 2014 BUSINESS WIRE
Nov 3, 2014 Consider The 2-3x Upside In This Most Overlooked Hepatitis B Stock Seeking Alpha
Nov 3, 2014 Bristol-Myers preparing to follow Gilead's lead on HCV drug pricing Seeking Alpha
Nov 3, 2014 Gilead: Slaying The Last Dragons Of Doubt? Seeking Alpha
Nov 3, 2014 Gilead's EPS Miss Is Investors' Gain: Gilead's A Buy On Harvoni Success Seeking Alpha
Nov 3, 2014 Why Did Gilead Drop Friday? Is It Justified Or Just An Overreaction? Seeking Alpha

1
2
3
4
5
6
7
8
next >
last >>

(0)

(0)